PI3K/mTOR pathway activation has been demonstrated in gastric cancer [38] and everolimus (Afinitor) has shown some significant response in the gastric cancer patients through targeting the mutations associated with PI3K/mTOR pathway [39], [40]. The gene discussed is PIK3CA; the disease is gastric cancer.